G. Egger

HDAC1 acts as tumor suppressor in ALK-positive anaplastic large-cell lymphoma: Implications for HDAC inhibitor therapy

This study shows HDAC1 suppresses ALK-positive lymphoma growth, but systemic HDAC inhibition can still be therapeutic.

Aggressive KRAS mutations direct TGF-β response towards partial EMT in patient-derived colorectal cancer tumoroids

This study investigates how TGF-β affects colorectal cancer tumoroids, finding that aggressive KRAS mutations lead to partial EMT and increased invasiveness.

JUN mediates senescence and immune cell recruitment to prevent prostate cancer progression

This study shows JUN suppresses prostate cancer progression by inducing senescence and immune cell recruitment, with JUN depletion accelerating tumor growth.

STAT3 restricts prostate cancer metastasis and antiandrogen resistance by controlling LKB1/CREB signaling pathway

This study identifies STAT3's role in restricting prostate cancer metastasis and antiandrogen resistance by regulating the LKB1/CREB signaling pathway in mouse models and human patients.

Mimicking tumor cell heterogeneity of colorectal cancer in a patient-derived organoid-fibroblast model

This paper develops a colorectal cancer organoid model incorporating patient-derived fibroblasts, showing enhanced cellular heterogeneity and morphology compared to mono-cultures.

Requirement of DNMT1 to orchestrate epigenomic reprogramming during NPM-ALK driven T cell lymphomagenesis

This study shows that DNMT1 is essential for maintaining tumor-specific methylation during NPM-ALK driven T cell lymphomagenesis, despite oncogenic signaling.

Thyroid and androgen receptor signaling are antagonized by CRYM in prostate cancer

This study shows that CRYM antagonizes thyroid and androgen signaling in prostate cancer and correlates with prognosis and PET imaging biomarkers.

STAT3-dependent systems-level analysis reveals PDK4 as an independent predictor of biochemical recurrence in prostate cancer

The paper identifies PDK4 as an independent prognostic marker for prostate cancer recurrence using gene co-expression networks and proteomics data.